Active Ingredient History
Crizotinib (trade name Xalkori, Pfizer, Inc.) is an anti cancer drug approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d’Origine Nantais (RON). Common adverse reactions in clinical trials with crizotinib, occurring at an incidence of 25% or higher, included visual disorders, nausea, diarrhea, vomiting, constipation, edema, elevated transaminases, and fatigue. Crizotinib is currently under investigational study for use in treatment of Uveal Melanoma. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma (Phase 2)
Adenocarcinoma of Lung (Phase 2)
Asthma (Phase 3)
Bile Duct Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Large Cell (Phase 1)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carotid Intima-Media Thickness (Phase 4)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Coronary Artery Disease (Phase 1)
Crizotinib (Phase 2)
Diabetes Mellitus, Type 2 (Phase 1)
Diffuse Intrinsic Pontine Glioma (Phase 1)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 2)
Glioblastoma (Phase 1)
Glioma (Phase 2)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 1)
HIV Infections (Phase 1)
Kidney Failure, Chronic (Phase 1)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 1)
Leukemia, Myeloid, Acute (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 4)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 2/Phase 3)
Multiple Myeloma (Phase 2)
Mutation (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Neuroblastoma (Phase 1/Phase 2)
Neurofibroma (Phase 1)
Neurofibromatosis 2 (Phase 2)
Oncogene Proteins (Phase 2)
Oncogenes (Phase 3)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pharmacokinetics (Phase 2)
Prostatic Neoplasms (Phase 2)
Proto-Oncogene Proteins c-met (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 1)
Rhabdomyosarcoma (Phase 2)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Thyroid Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Vestibular Diseases (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue